Examination of Patients Using Paliperidone Palmitate 3-Month Formulation

Authors : Mehmet Hamdi ÖRÜM

Pages : 68-70

View : 56 | Download : 46

Publication Date : 2023-06-22

Article Type : Other Papers

Abstract :Adherence problems to oral antipsychotics are common in patients with psychotic disorders. The use of long-acting injectable antipsychotics has been suggested to support adherence management. This study aimed to examine the patients who used paliperidone palmitate 3-month formulation insert ignore into journalissuearticles values(PP3M);. Twenty-one patients insert ignore into journalissuearticles values(8 females and 13 males); were included in the study. The mean age was 40.90±10.98 years, the age of disorder onset was 18.47±3.64 years, the duration of paliperidone palmitate once-monthly formulation use was 12.38±14.68 months, the duration of PP3M use was 4.66±1.85 months. While 20 patients were diagnosed with schizophrenia, 1 male patient was diagnosed with schizoaffective disorder. Since PP3M does not require long-term continuous drug use and follow-up, its use in patients with adherence problems provides significant benefits.
Keywords : Paliperidone palmitate three month long acting injection, patient compliance, schizophrenia, schizoaffective disorder

ORIGINAL ARTICLE URL